Godavari Biorefineries Ltd announced on July 3, 2025, that it has been granted a patent in Europe for its novel anti-cancer molecule. The patent, which covers a highly potent compound with proven efficacy on cancer and cancer stem cells, is now validated in Spain, the UK, and as a Unitary Patent across Europe.
The company stated that the patent falls under the “Anti-Cancer Research Segment”, emphasizing the molecule’s effectiveness in combating cancer and targeting cancer stem cells — a crucial focus area in modern oncology research.
The announcement was made through a regulatory filing to the National Stock Exchange of India and BSE Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
“This patent reinforces our commitment to developing breakthrough solutions in cancer therapy, addressing one of the most challenging areas in medical science,” the company said in its communication.
The company also noted that this development is part of its ongoing research and innovation efforts and is expected to contribute to its growth in the healthcare and biotech segment.
For your records and information, the disclosure was signed digitally by Manoj Jain, Company Secretary and Compliance Officer at Godavari Biorefineries.
